Unlike AR+ LNCaP, AR− prostate cancer cells PC3, which also have a null mutation in the TP53 gene and a loss of PTEN, are resistant to fumiquinazoline-induced growth suppression. This evidence concerns the gene TP53 and prostate carcinoma.